Artigo Acesso aberto Revisado por pares

Laboratory Findings, Compassionate Use of Favipiravir, and Outcome in Patients With Ebola Virus Disease, Guinea, 2015—A Retrospective Observational Study

2019; Oxford University Press; Volume: 220; Issue: 2 Linguagem: Inglês

10.1093/infdis/jiz078

ISSN

1537-6613

Autores

Romy Kerber, Eva Lorenz, Sophie Duraffour, Daouda Sissoko, Martin Rudolf, Anna Jaeger, Sékou Ditinn Cissé, Alseny-Modet Camara, Osvaldo Miranda, Carlos M. de Castro, Joseph Akoi Boré, Fara Raymond Koundouno, Johanna Repits, Babak Afrough, Beate Becker‐Ziaja, Julia Hinzmann, Marc Mertens, Inês Vitoriano, Christopher H. Logue, Jan-Peter Böttcher, Elisa Pallasch, Andreas Sachse, Amadou Bah, Mar Cabeza-Cabrerizo, Katja Nitzsche, Eeva Kuisma, Janine Michel, Tobias Holm, Elsa Gayle Zekeng, Lauren A. Cowley, Isabel García-Dorival, Nicole Hetzelt, Jonathan H. J. Baum, Jasmine Portmann, Lisa Carter, Rahel Lemma Yenamaberhan, A Camino, Theresa Enkirch, Katrin Singethan, Sarah Meisel, Antonio Mazzarelli, A. Kosgei, Liana E. Kafetzopoulou, Natasha Y. Rickett, Livia Victoria Patrono, Luam Ghebreghiorghis, Ulrike Arnold, Géraldine Colin, Sylvain Juchet, Laura March, Jacques Séraphin Kolié, Abdoul Habib Béavogui, Stephanie Wurr, Sabrina Bockholt, Ralf Krumkamp, Jürgen May, Kilian Stoecker, Erna Fleischmann, Giuseppe Ippolito, Miles W. Carroll, Lamine Koivogui, N’Faly Magassouba, Sakoba Keita, Céline Gurry, Patrick Drury, Boubacar Diallo, Pierre Formenty, Roman Wölfel, Antonino Di, Martin Gabriel, Xavier Anglaret, Denis Malvy, Stephan Günther,

Tópico(s)

COVID-19 epidemiological studies

Resumo

Abstract Background In 2015, the laboratory at the Ebola treatment center in Coyah, Guinea, confirmed Ebola virus disease (EVD) in 286 patients. The cycle threshold (Ct) of an Ebola virus–specific reverse transcription–polymerase chain reaction assay and 13 blood chemistry parameters were measured on admission and during hospitalization. Favipiravir treatment was offered to patients with EVD on a compassionate-use basis. Methods To reduce biases in the raw field data, we carefully selected 163 of 286 patients with EVD for a retrospective study to assess associations between potential risk factors, alterations in blood chemistry findings, favipiravir treatment, and outcome. Results The case-fatality rate in favipiravir-treated patients was lower than in untreated patients (42.5% [31 of 73] vs 57.8% [52 of 90]; P = .053 by univariate analysis). In multivariate regression analysis, a higher Ct and a younger age were associated with survival (P < .001), while favipiravir treatment showed no statistically significant effect (P = .11). However, Kaplan-Meier analysis indicated a longer survival time in the favipiravir-treated group (P = .015). The study also showed characteristic changes in blood chemistry findings in patients who died, compared with survivors. Conclusions Consistent with the JIKI trial, this retrospective study revealed a trend toward improved survival in favipiravir- treated patients; however, the effect of treatment was not statistically significant, except for its influence on survival time.

Referência(s)